ProBio launches GMP AAV manufacturing at New Jersey facility

CDMO ProBio has added cGMP adeno-associated virus (AAV) manufacturing services at its recently opened Hopewell, New Jersey facility.

ProBio officially announced the opening of the flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell back in June. The 128,000-square-foot GMP facility is purpose-built to provide end-to-end AAV manufacturing solutions that align with global regulatory and quality standards. It will also make high-quality plasmid DNA and viral vectors, including AAV and lentiviral platforms. The enhancements will enable ProBio to support a broader range of therapeutic candidates from early proof-of-concept through clinical readiness, all from one integrated site.

ProBio's GMP AAV manufacturing services include flexible batch sizes from 50L to 200L, with capability for 2 x 200L concurrent runs — supporting early clinical to late-phase programs. Additionally, comprehensive internal QC and analytical capabilities enable fast, phase-appropriate release while maintaining high standards of precision and compliance.